首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure
【2h】

Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure

机译:靶向磷酸二酯酶5作为针对心肌缺血/再灌注损伤和心力衰竭的治疗选择

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Phosphodiesterase type 5 (PDE5) selectively hydrolyses the second messenger cGMP into 5′‐GMP, thereby regulating its intracellular concentrations. Dysregulation of the cGMP‐dependent pathway plays a significant role in various cardiovascular diseases. Therefore, its modulation by drugs, such as PDE5 inhibitors, may represent an effective therapeutic approach. There are currently four PDE5 inhibitors available for the treatment of erectile dysfunction: sildenafil, vardenafil, tadalafil and avanafil. Sildenafil and tadalafil have also received Food and Drug Administration approval for the treatment of pulmonary arterial hypertension. This review summarizes the pharmacological aspects and clinical potential of PDE5 inhibition for the treatment of myocardial ischaemia/reperfusion injury and heart failure.
机译:5型磷酸二酯酶(PDE5)将第二个信使cGMP选择性水解为5'-GMP,从而调节其细胞内浓度。 cGMP依赖性途径的失调在各种心血管疾病中起重要作用。因此,其受药物(例如PDE5抑制剂)的调节可能代表一种有效的治疗方法。目前有四种可用于治疗勃起功能障碍的PDE5抑制剂:西地那非,伐地那非,他达拉非和阿伐那非。西地那非和他达拉非也已获得食品药品监督管理局的批准用于治疗肺动脉高压。这篇综述总结了PDE5抑制作用在治疗心肌缺血/再灌注损伤和心力衰竭中的药理作用和临床潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号